ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BPCR Biopharma Credit Plc

0.876
0.00 (0.00%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Credit Plc LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.876 0.876 0.878 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 135.74M 108.45M 0.0833 10.56 1.15B

BioPharma Credit PLC Notice of Half Year Results (6453X)

31/08/2022 7:01am

UK Regulatory


Biopharma Credit (LSE:BPCR)
Historical Stock Chart


From Apr 2022 to Apr 2024

Click Here for more Biopharma Credit Charts.

TIDMBPCR

RNS Number : 6453X

BioPharma Credit PLC

31 August 2022

31 August 2022

BIOPHARMA CREDIT PLC

(the "Company")

NOTICE OF HALF YEAR RESULTS

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its Half Year Results for the period ending 30 June 2022 on Wednesday, 14 September 2022.

A management presentation will be delivered at 14.00 BST through a webcast facility. To register to attend or request details, RSVP to biopharmacredit@buchanan.uk.com .

-Ends-

Enquiries

BioPharma Credit PLC

via Link Company Matters Limited

Company Secretary

+44 (0) 1392 477 500

Buchanan

+44 (0)20 7466 5000

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORWPUUPRUPPGAU

(END) Dow Jones Newswires

August 31, 2022 02:01 ET (06:01 GMT)

1 Year Biopharma Credit Chart

1 Year Biopharma Credit Chart

1 Month Biopharma Credit Chart

1 Month Biopharma Credit Chart

Your Recent History

Delayed Upgrade Clock